Gut Microbiome and Drug-Induced Liver Injury - EMJ

This site is intended for healthcare professionals

Gut Microbiome Changes Linked to Drug-Induced Liver Injury

Author:

Key Summary:

  • Researchers examined gut microbiome and metabolic changes in drug-induced liver injury.
  • Three metabolites showed potential for distinguishing patients with liver injury from healthy controls.
  • Findings highlighted candidate biomarkers requiring validation in larger independent studies.
Drug-induced liver injury

Drug-induced liver injury (DILI) was associated with changes in gut bacteria and circulating metabolites, according to a study investigating potential biomarkers for identifying the condition and assessing its severity.   

Findings suggest that combining gut microbiome and metabolomic profiles could help characterise DILI, although further research is needed before these markers can be considered for clinical use. 

Investigating the Gut–Liver Axis in DILI 

Researchers recruited 56 participants, comprising 33 patients with DILI and 23 healthy controls, to investigate the relationship between gut microbial composition and systemic metabolic changes. The DILI group was further divided into patients with mild disease (n=21) and moderate-to-severe disease (n=12). 

Blood samples were analysed using untargeted metabolomics, while faecal samples underwent 16S ribosomal RNA sequencing. Researchers then examined associations between altered bacterial populations and circulating metabolites. 

Compared with healthy controls, patients with DILI had reduced gut microbial richness and diversity, alongside differences in bacterial composition. 

Metabolites Show Potential as Candidate Biomarkers 

Correlation analysis identified three metabolites associated with microbial changes: glycocholic acid, carnosine, and valylphenylalanine (Val-Phe). Individual analyses showed apparent discriminatory performance, with Val-Phe achieving the highest area under the receiver operating characteristic curve (AUC) at 0.992. A combined model achieved an apparent AUC of 1.000. 

Researchers also identified metabolic and microbial differences between mild and moderate-to-severe DILI. A separate model incorporating three severity-associated metabolites achieved an apparent AUC of 0.885. 

Further Validation Is Needed 

Findings suggest that gut microbial and metabolic changes are associated with DILI and may provide useful avenues for biomarker research. However, researchers cautioned that the apparent diagnostic performance of the combined models may reflect overfitting, given the small sample size and absence of independent validation. 

Researchers concluded that these microbiota-associated metabolites represent exploratory candidate biomarkers for distinguishing DILI from healthy controls and assessing disease severity. Larger independent studies and further mechanistic research are needed to establish their diagnostic value. 

Reference 

Yin L et al. The landscape and interplay of gut microbiome and metabolites in drug-induced liver injury.Eur J Med Res. 2026; DOI: 10.1186/s40001-026-05407-4.

Featured Image: Grispb on Adobe Stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.